Aspira Women’s Health price target lowered to $3.30 from $4 at Cantor Fitzgerald

Cantor Fitzgerald analyst Ross Osborn lowered the firm’s price target on Aspira Women’s Health to $3.30 from $4 and keeps a Neutral rating on the shares. Aspira Women’s Health reported Q2 revenue below consensus estimates and exited 2023 with $2.9M in cash, cash equivalents, and restricted cash, and has guided to a 2024 burn of $15M-$18M, the analyst tells investors in a research note. The firm believes the company will need to raise capital in the near-term and does not think OvaWatch, the company’s most recent offering, will produce sufficient revenue to eliminate the need for a raise.